Fredric B Weihmuller is an accomplished inventor based in Huntington Beach, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of oral dosage forms for hormone delivery. With a total of two patents to his name, Weihmuller's work focuses on improving the efficacy and delivery methods of progesterone.

Latest Patents

Weihmuller's latest patents include innovative dosage forms and methods for the oral delivery of progesterone. One of his notable inventions involves oral progesterone unit dosage forms that comprise micronized progesterone and a solid polymeric carrier. These dosage forms are designed to provide a therapeutically effective blood level of progesterone, ranging from about 0.1 ng/ml to about 400 ng/ml upon oral administration. Additionally, the dosage forms can be prepared for both immediate and sustained release. Another patent details an oral dosage form suitable for delivering a combined dosage of progesterone, which ensures a blood concentration within the same therapeutic range.

Career Highlights

Fredric B Weihmuller has been associated with Watson Pharmaceuticals, Inc., where he has contributed to the advancement of pharmaceutical formulations. His work has focused on creating effective hormone therapies that can significantly improve patient outcomes. Weihmuller's expertise in the field has positioned him as a key player in the development of innovative drug delivery systems.

Collaborations

Throughout his career, Weihmuller has collaborated with notable colleagues, including David Chung Hsia and Thomas Ho. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical products.

Conclusion

Fredric B Weihmuller's contributions to the field of hormone delivery through his innovative patents have made a significant impact on pharmaceutical sciences. His work continues to pave the way for advancements in effective hormone therapies.